InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has granted the drug priority review status due to the unmet medical need it addresses.